Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Summary

This is a pilot study of sorafenib in patients with BRAF Mutation Refractory Solid Tumors. This study is a single-arm, pilot study of sorafenib in patients with Refractory Solid Tumors harboring BRAF Mutation Sorafenib 400 mg will be administered orally twice a day for 28 days. To investigate the efficacy of sorafenib in patients with Refractory Solid Tumors harboring BRAF Mutation.

Timeline

Start

2016-05-30

Primary completion

2016-08

Completion

2016-08-09

Drugs

Indications